
Lazard just posted Q3 2026 earnings and the stock barely flinched, slipping around 0.2% to about $37 after the release. Price action looked almost bored. The headline numbers were not. Financial Advisory turned in record third quarter revenue while Asset Management delivered record management fees, giving the firm an earnings rebound from a soft Q2.
That disconnect matters. A flat one day move after stronger advisory income and firmer fee revenue suggests investors are still weighing past margin pressure and balance sheet concerns more heavily than the latest operating progress.
Impressed by Lazard’s record advisory and fee income but uneasy about past margin and balance sheet worries still hanging over the share price reaction? Consider using our list of solid balance sheet and fundamentals stocks (26 results) to compare LAZ with peers that pair stable finances with cleaner balance sheets.
Skip the headline revenue growth. Ask Charlie what Lazard isn’t saying about Lazard CL targets.
Bulls argue Lazard can shift toward richer fee pools and higher earnings power if recent investments translate into stickier advisory and asset management income.
"The main requirement for this thesis is that Lazard converts its recent build out in private capital advisory, asset management inflows, and new MD cohorts into sustained advisory revenue per MD and fee based asset growth."
Q3 gives partial support. Record Financial Advisory revenue and record management fees show the expanded bench and product set are producing higher fee activity. Asset Management posted strong year to date inflows and AUM of US$284b, which indicates traction on the fee based growth leg. Net income and EPS pressure, though, shows margin uplift is not yet following that revenue mix progress.
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all.
The key worry around Lazard is that richer fee pools cannot outpace a heavy pay structure and churn in senior bankers.
"The intentional turnover of more than 80 advisory MDs since 2022 and the addition of about 90 new MDs has created a cohort where roughly 40% of advisory MDs are still in their first three years on the platform."
Record advisory revenue shows the refreshed bench can win work. However, the sharp fall in adjusted net income and EPS signals earnings are not keeping up with that activity. Net income excluding extra items fell much faster than revenue rose. That gap suggests the high fixed compensation load and onboarding costs for newer MDs remain a key milestone not yet cleared.
Lazard just showed how a better quarter can still meet a muted share price reaction. The real opportunity lies in finding stocks that could be undervalued before the market corrects them.
That is three of the list. See the full list of 30 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com